Drugs / ADENOVIRUS/PSA VACCINE
ADENOVIRUS/PSA VACCINE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00583024 | Dec 2007 → Dec 2020 | hormone-resistant prostate carcinoma | David M Lubaroff | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADENOVIRUS/PSA VACCINE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00583024 ↗ |
| Known as | Ad/PSA product | “This is a virus vaccine in which the gene for prostate specific antigen (PSA) has been placed into a common cold virus termed adenovirus (Ad) to produce this Ad/PSA product.” NCT00583024 ↗ |
| Known as | Ad/PSA vaccine | “This investigational study involves treatment with an Ad/PSA vaccine for men with prostate cancer who present with evidence of hormone refractory metastatic disease.” NCT00583024 ↗ |
| Action | Deplete | “the vaccination and ensuing anti-PSA immunity will kill the prostate cancer cells.” NCT00583024 ↗ |
| Modality | Vaccine | “This is a virus vaccine” NCT00583024 ↗ |
| Route | Subcutaneous | “of the Ad/PSA subcutaneously” NCT00583024 ↗ |